Information Provided By: 
Fly News Breaks for March 21, 2018
CELG, PRTA
Mar 21, 2018 | 07:31 EDT
Cantor Fitzgerald analyst William Tanner raised his price target for Prothena to $69 following the company's collaboration agreement with Celgene (CELG). The collaboration with Celgene shows that an industry-leader sees the value of Prothena's capabilities in developing therapies of significant medical and commercial potential, Tanner tells investors in a research note. The agreement also allows for "speed and capital efficiency to get to de-risking events," the analyst adds. He reiterates an Overweight rating on Prothena.
News For PRTA;CELG From the Last 2 Days
There are no results for your query PRTA;CELG
